Corvus Pharmaceuticals, Inc 8-K, filed Jun 21, 2023
Corvus Pharmaceuticals, Inc. (CRVS)
About this 8-K
Corvus Pharmaceuticals, Inc filed this 8-K on June 21, 2023, reporting on events of June 15, 2023.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule
405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 15, 2023, Corvus Pharmaceuticals, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). Only stockholders of record at the close of business on April 18, 2023, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, there were 46,568,511 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 36,151,036 shares of the Company’s common stock were voted in person or by proxy for the three proposals set forth below, each of which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 28, 2023.
The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:
Proposal No. 1 — Election of Directors
The Company’s stockholders elected the Class I director nominees below to the Company’s Board of Directors to hold office until the 2026 Annual Meeting of Stockholders or until their respective successors are elected and qualified or appointed, or the earlier of their death, resignation or removal.
| Class I Director Nominees | Votes For | Votes Withheld | Broker Non-Votes | |||||||||
| Richard A. Miller, M.D. | 26,009,538 | 68,027 | 10,073,471 | |||||||||
| Linda S. Grais, M.D. J.D. | 25,210,111 | 867,454 | 10,073,471 | |||||||||
Proposal No. 2 — Ratification of Selection of Independent Registered Accounting Firm
The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLC as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.
| Votes For | Votes Against | Abstain | ||||||||
| 35,873,795 | 104,973 | 172,268 | ||||||||
Proposal No. 3 —Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers
On a non-binding advisory basis, the Company’s stockholders approved the compensation of the Company’s named executive officers.
| Votes For | Votes Against | Abstain | Broker Non-Votes | |||||||||||
| 25,550,695 | 348,929 | 177,941 | 10,073,471 | |||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CORVUS PHARMACEUTICALS, INC. | |||
| Date: June 20, 2023 | By: | /s/ Leiv Lea | |
| Leiv Lea | |||
| Chief Financial Officer | |||